Patents by Inventor Xin Xiao Zheng

Xin Xiao Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9346876
    Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 24, 2016
    Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vijay K. Kuchroo, Terry Barton Strom, Eugene K. Cha, Sumone Chakravarti, Catherine Anne Sabatos-Peyton, Chen Zhu, Xin Xiao Zheng, Alberto Sanchez-Fueyo
  • Publication number: 20150079085
    Abstract: The invention relates to methods of modulating immune responses in a subject such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.
    Type: Application
    Filed: October 1, 2014
    Publication date: March 19, 2015
    Inventors: Vijay K. Kuchroo, Sumone Chakravarti, Terry Strom, Xin Xiao Zheng, Jennifer Meyers
  • Publication number: 20140348842
    Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.
    Type: Application
    Filed: April 29, 2014
    Publication date: November 27, 2014
    Applicants: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vijay K. Kuchroo, Terry Strom, Eugene K. Cha, Sumone Chakravarti, Catherine Sabatos, Chen Zhu, Xin Xiao Zheng, Alberto Sanchez-Fueyo
  • Patent number: 8329660
    Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.
    Type: Grant
    Filed: October 4, 2004
    Date of Patent: December 11, 2012
    Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vijay K. Kuchroo, Terry Strom, Eugene K. Cha, Sumone Chakravarti, Catherine Sabatos, Chen Zhu, Xin Xiao Zheng, Alberto Sanchez-Fueyo
  • Publication number: 20110045002
    Abstract: The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.
    Type: Application
    Filed: April 26, 2010
    Publication date: February 24, 2011
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. Kuchroo, Sumone Chakravarti, Terry Strom, Xin Xiao Zheng, Jennifer Hartt Meyers
  • Publication number: 20100291054
    Abstract: The invention provides isolated regulatory T cells and methods of obtaining regulatory T cells. The invention also provides methods for inhibiting an antigen-specific immune response (e.g., graft rejection, an autoimmune disorder, graft versus host disease, a response to a tumor cell, a response to an infection, and a response to an allergen) in a subject requiring administering an isolated regulatory T cell to the subject. The invention further provides methods for treating or modulating an antigen-specific immune response in a subject requiring administering a regulatory T cell to the subject.
    Type: Application
    Filed: November 28, 2007
    Publication date: November 18, 2010
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Xin Xiao Zheng, Dong Zhang
  • Patent number: 7741271
    Abstract: The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: June 22, 2010
    Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vijay K. Kuchroo, Sumone Chakravarti, Terry Strom, Xin Xiao Zheng, Jennifer Meyers
  • Patent number: 7579439
    Abstract: The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells in vivo. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant ex vivo), reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharamaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: August 25, 2009
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Terry B. Strom, Xian Chang Li, Xin Xiao Zheng
  • Publication number: 20080089894
    Abstract: The invention relates to methods of inducing tolerance and preventing transplant rejection by blocking costimulatory signals and using immunosuppressive agents, preferably rapamycin, to prevent late rejection episodes, yet not block tolerance inducing T-cell specific depletion; compositions and kits for use in such methods are also provided herein.
    Type: Application
    Filed: December 5, 2007
    Publication date: April 17, 2008
    Inventors: Terry Strom, Xin Xiao Zheng
  • Patent number: 7347995
    Abstract: Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: March 25, 2008
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Terry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari-Lacraz
  • Patent number: 7018626
    Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: March 28, 2006
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Publication number: 20040219148
    Abstract: Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.
    Type: Application
    Filed: May 25, 2004
    Publication date: November 4, 2004
    Applicant: Beth Israel Deaconess Medical Center, Inc., a Massachusetts corporation
    Inventors: Terry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari-Lacraz
  • Patent number: 6797263
    Abstract: Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: September 28, 2004
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Terry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari-Lacraz
  • Patent number: 6770272
    Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: August 3, 2004
    Assignee: Beth Israel Hospital Association
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Publication number: 20030026778
    Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.
    Type: Application
    Filed: May 14, 2002
    Publication date: February 6, 2003
    Applicant: Beth Israel Hospital Association, a Massachusetts corporation
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Publication number: 20020173628
    Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.
    Type: Application
    Filed: May 14, 2002
    Publication date: November 21, 2002
    Applicant: Beth Israel Hospital Association
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Publication number: 20020128436
    Abstract: Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.
    Type: Application
    Filed: May 14, 2001
    Publication date: September 12, 2002
    Inventors: Terry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari Lacraz
  • Patent number: 6410008
    Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: June 25, 2002
    Assignee: Beth Israel Hospital Association
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Patent number: 6403077
    Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.
    Type: Grant
    Filed: November 6, 1997
    Date of Patent: June 11, 2002
    Assignee: Beth Israel Hospital Association
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele